Jubilant Life Sciences has registered consolidated net profit of Rs.152 crore during the second quarter ended September 2012 as compared to Rs.79.36 crore in the corresponding period of last year. The higher profit is mainly on account of gain of Rs.49.46 crore as foreign exchange gains as compared to loss of Rs.42.60 crore in the corresponding period of last year. Its EBDITA improved by 9.1 per cent to Rs.263.72 crore from Rs.241.80 crore.

The company's consolidated net sales improved by 16.1 per cent to Rs.1219.73 crore from Rs.1050.47 crore in the similar period of last year. The sales of pharmaceutical segment improved by 17 per cent to Rs.650 crore and contributed 53 per cent to the revenue mix. The segment EBDITA stood at Rs.174 crore. During the second quarter, it received US FDA approval for four ANDAs viz., escitalopram, losartan potassium, losartan plus HCTZ and olanzapine OD tablets.

The ingredients segment comprises of proprietary products and exclusive synthesis, nutrition ingredients and life science chemicals has posted income of Rs.575 crore, up by 15 per cent and contributed 47 per cent to the overall revenue mix.

The company's revenues from North America increased by 29 per cent to Rs.512 crore contributing 42 per cent to the revenue mix. Its revenue from Europe and Japan improved by 29 per cent to Rs.240 crore thereby contributing 20 per cent to the revenue mix. Revenue from rest of the world reached at Rs.136 crore with a growth of 15 per cent. Jubilants' domestic revenue moved up by 4 per cent to Rs.337 crore with a contribution of 27 per cent to the revenue mix.

Commenting on the performance, Shyam S Bhartia, chairman & managing director and Hari S Bhartia, co-chairman & managing director, said, “We are happy to report that revenue and operating profit growth is in line with our expectation. Continued focus on enhancing market shares across business lines, new product launches in both segments and enhanced capacity utilisation would drive achievement of annual guidance given earlier.”

For the first half ended September 2012, its consolidated net sales increased by 23.5 per cent to Rs.2456 crore from Rs.1992 crore in the same period of last year. Its net profit increased marginally to Rs.157.01 crore from Rs.156.48 crore. Earnings per share worked out to Rs.9.85 for the first half of FY'13 as against Rs.9.82 in the last period.